http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2062504-T3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D453-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D453-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435
filingDate 1989-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 1994-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8633ac38cd040b008cf235c3028a7b18
publicationDate 1994-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber ES-2062504-T3
titleOfInvention THERAPEUTIC AGENTS OF QUINUCLIDINE.
abstract A SERIES OF CIS -3 [ARYLMETHYL (SUBSTITUTED ALPHA)] QUINUCLIDINES, 3- [METHYLAMINE (CYCLIC)] AND ACUTEALLY ACCEPTABLE CIS IS PRESENTED. THESE PARTICULAR COMPOUNDS ARE USEFUL AS ANTAGONISTS P AND ALSO, HAVE GREAT VALUE IN THE TREATMENT OF GASTROINTESTINAL DISEASES, DISEASES OF THE CENTRAL NERVOUS SYSTEM, INFLAMMATORY DISEASES OR PAIN OR MIGRAINE. PREFERRED COMPOUNDS INCLUDE ETHYLAMINE CIS ((2-TRIFUOROPHENYL)] CIS METHODS ARE ALSO SUPPLIED TO PREPARE THESE COMPOUNDS FROM KNOWN INITIATOR MATERIALS.
priorityDate 1988-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6329
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419490133
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6341
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553636
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7527
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419544759

Total number of triples: 37.